{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:12:09Z","timestamp":1777417929498,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,3]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review available data related to the use of prostaglandin analogs (bimatoprost, latanoprost, travoprost, unoprostone) in the management of ocular hypertension and open-angle glaucoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Primary and review articles were identified from a MEDLINE search (1966\u2013May 2001) and requested information from product manufacturers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION AND DATA EXTRACTION:<\/jats:title>\n                    <jats:p>All available information, including that published in articles and abstracts, which was deemed relevant was included in this review. Limited data have been published to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>The prostaglandin analogs appear to be effective, well-tolerated agents for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma and ocular hypertension. This drug class offers an alternative for patients who do not achieve control with another topical antiglaucoma agent or for those with a contraindication to first-line therapy with \u03b2-adrenergic antagonists. Based on preliminary clinical data, bimatoprost, latanoprost, and travoprost appear to be at least as effective as timolol, while the effectiveness of unoprostone is similar or slightly less. Prostaglandin analogs may be used in conjunction with other antiglaucoma medications, although further studies must establish the optimal combination. Whether clinical experience will yield outcomes in favor of one of the prostaglandin analogs remains to be determined. Patients should be educated on adverse events associated with prostaglandin analogs, particularly the potential for changes in the pigmentation of the iris and eyelashes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Bimatoprost, latanoprost, and travoprost appear to be equivalent to the current standard of therapy in the topical treatment of elevated IOP. Further clinical data published in article versus abstract format is required to better assess potential differences among these 3 agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a178","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:20:40Z","timestamp":1054743640000},"page":"504-511","source":"Crossref","is-referenced-by-count":71,"title":["Prostaglandin Analog Treatment of Glaucoma and Ocular Hypertension"],"prefix":"10.1177","volume":"36","author":[{"given":"Christy L","family":"Alexander","sequence":"first","affiliation":[{"name":"Christy L Alexander, PharmD Student, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J","family":"Miller","sequence":"additional","affiliation":[{"name":"Sarah J Miller PharmD, at time of writing, Drug Information Resident, School of Pharmacy and Pharmacal Sciences\/Eli Lilly and Company, Purdue University, Indianapolis, IN; now, Global Medical Information Administrator, Eli Lilly and Company, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R","family":"Abel","sequence":"additional","affiliation":[{"name":"Steven R Abel PharmD, FASHP, Head, Department of Pharmacy Practice, School of Pharmacy and Pharmacal Sciences, Purdue University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,3,1]]},"reference":[{"key":"bibr-bibr1-aph.1A178","unstructured":"FDA approves two new intraocular pressure lowering drugs for the management of glaucoma. Press release March 16, 2001 [accessed 2001 May 3]. Available at URL: http:\/\/www.fda.gov\/bbs\/topics\/news\/2001\/new00757.html."},{"key":"bibr-bibr2-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199810293391808"},{"key":"bibr-bibr3-aph.1A178","unstructured":"Lewis TL, Barnebey HS, Bartlett JD, Blume AJ, Fingeret M, Lalle PA, Care of the patient with open angle glaucoma: reference guide for clinicians. Prepared by the American Optometric Association. Updated 5\/28\/99 [accessed 2001 May 23]. Available at URL: http:\/\/www.aoanet.org\/cpg-9-cpoag.html."},{"key":"bibr-bibr4-aph.1A178","first-page":"200","volume-title":"General ophthalmology","author":"Riordan-Eva P","year":"1999","edition":"15"},{"key":"bibr-bibr5-aph.1A178","first-page":"370","volume-title":"General ophthalmology","author":"Whitcher JP","year":"1999","edition":"15"},{"key":"bibr-bibr6-aph.1A178","first-page":"1466","volume-title":"Pharmacotherapy: A pathophysiologic approach","author":"Lesar TS","year":"1999","edition":"4"},{"key":"bibr-bibr7-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)76896-5"},{"key":"bibr-bibr8-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1159\/000310397"},{"key":"bibr-bibr9-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(99)00387-6"},{"key":"bibr-bibr10-aph.1A178","volume-title":"Package insert. Lumigan (bimatoprost)","year":"2001"},{"key":"bibr-bibr11-aph.1A178","volume-title":"Package insert. Travatan (travoprost)","year":"2001"},{"key":"bibr-bibr12-aph.1A178","volume-title":"Package insert. Xalatan (latanoprost)","year":"2000"},{"key":"bibr-bibr13-aph.1A178","volume-title":"Package insert. Rescula (unoprostone)","year":"2000"},{"key":"bibr-bibr14-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.4.721"},{"key":"bibr-bibr15-aph.1A178","volume-title":"Travatan (travoprost ophthalmic solution 0.004%)","year":"2001"},{"key":"bibr-bibr16-aph.1A178","volume-title":"Rescula (unoprostone isopropyl ophthalmic solution) 0.15%","year":"2001"},{"key":"bibr-bibr17-aph.1A178","volume-title":"Lumigan (bimatoprost ophthalmic solution 0.03%)","year":"2001"},{"key":"bibr-bibr18-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1159\/000027290"},{"key":"bibr-bibr19-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00002"},{"key":"bibr-bibr20-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(01)00219-3"},{"key":"bibr-bibr21-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01337-X"},{"key":"bibr-bibr22-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200110000-00010"},{"key":"bibr-bibr23-aph.1A178","first-page":"S557","volume":"42","author":"Whitson JT","year":"2001","journal-title":"Invest Ophthalomol Vis Sci"},{"key":"bibr-bibr24-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01177-1"},{"key":"bibr-bibr25-aph.1A178","first-page":"S559","volume":"42","author":"Robertson SM","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"bibr-bibr26-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30750-1"},{"key":"bibr-bibr27-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(95)30798-1"},{"key":"bibr-bibr28-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30407-7"},{"key":"bibr-bibr29-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90115-X"},{"key":"bibr-bibr30-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6257(01)00212-0"},{"key":"bibr-bibr31-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(00)00495-4"},{"key":"bibr-bibr32-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1097\/00061198-200004000-00010"},{"key":"bibr-bibr33-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.1.12"},{"key":"bibr-bibr34-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.78.12.899"},{"key":"bibr-bibr35-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(97)30110-9"},{"key":"bibr-bibr36-aph.1A178","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(01)01257-0"},{"key":"bibr-bibr37-aph.1A178","volume-title":"2001 Drug topics redbook","year":"2001"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:06:08Z","timestamp":1777374368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["10.1345\/aph.1A178"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a178","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}